Boston Scientific Co. (NYSE:BSX) EVP Sells $127,678.31 in Stock

Boston Scientific Co. (NYSE:BSX) EVP John Bradley Sorenson sold 1,201 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $106.31, for a total value of $127,678.31. Following the sale, the executive vice president now directly owns 25,443 shares of the company’s stock, valued at approximately $2,704,845.33. This trade represents a 4.51 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

John Bradley Sorenson also recently made the following trade(s):

• On Tuesday, February 18th, John Bradley Sorenson sold 2,657 shares of Boston Scientific stock. The shares were sold at an average price of $104.41, for a total transaction of $277,417.37.
• On Wednesday, February 12th, John Bradley Sorenson sold 6,389 shares of Boston Scientific stock. The shares were sold at an average price of $105.06, for a total transaction of $671,228.34.
• On Friday, February 7th, John Bradley Sorenson sold 6,528 shares of Boston Scientific stock. The stock was sold at an average price of $104.97, for a total transaction of $685,244.16.
• On Thursday, January 2nd, John Bradley Sorenson sold 4,119 shares of Boston Scientific stock. The shares were sold at an average price of $90.02, for a total value of $370,792.38.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $105.41 on Friday. The business has a fifty day moving average price of $97.69 and a 200-day moving average price of $89.06. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. The company has a market capitalization of $155.36 billion, a PE ratio of 84.33, a PEG ratio of 2.79 and a beta of 0.80. Boston Scientific Co. has a 1-year low of $65.33 and a 1-year high of $107.17.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 18.11%. As a group, equities analysts expect that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on BSX. Canaccord Genuity Group lifted their price objective on Boston Scientific from $98.00 to $101.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Wells Fargo & Company lifted their price target on shares of Boston Scientific from $100.00 to $118.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. Deutsche Bank Aktiengesellschaft upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price objective for the company in a report on Friday, January 10th. Citigroup raised their target price on shares of Boston Scientific from $107.00 to $122.00 and gave the stock a “buy” rating in a research report on Thursday, February 6th. Finally, Sanford C. Bernstein boosted their price target on shares of Boston Scientific from $92.00 to $100.00 and gave the company an “outperform” rating in a research report on Thursday, October 24th. Two analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $107.39.

Hedge Funds Weigh In On Boston Scientific

Hedge funds have recently added to or reduced their stakes in the company. Creative Planning increased its holdings in shares of Boston Scientific by 7.7% in the 3rd quarter. Creative Planning now owns 204,208 shares of the medical equipment provider’s stock worth $17,113,000 after purchasing an additional 14,663 shares in the last quarter. Global Retirement Partners LLC boosted its position in shares of Boston Scientific by 11.5% during the third quarter. Global Retirement Partners LLC now owns 4,370 shares of the medical equipment provider’s stock valued at $366,000 after buying an additional 449 shares during the last quarter. Stratos Wealth Advisors LLC increased its holdings in Boston Scientific by 8.9% in the 3rd quarter. Stratos Wealth Advisors LLC now owns 6,419 shares of the medical equipment provider’s stock worth $538,000 after buying an additional 522 shares in the last quarter. Blue Trust Inc. raised its position in Boston Scientific by 91.6% in the 3rd quarter. Blue Trust Inc. now owns 10,492 shares of the medical equipment provider’s stock worth $808,000 after buying an additional 5,017 shares during the last quarter. Finally, Capital Investment Advisors LLC purchased a new position in Boston Scientific in the 3rd quarter worth about $217,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.